ArcticZymes Technologies — Board/Management Information 2022

Dec 1, 2022

ArcticZymes Technologies appoints a Chief Scientific Officer (CSO)

Tromsø, Norway, 1 st December 2022 – ArcticZymes Technologies ASA (OSE: AZT) announces the appointment of Dr. Darren Ellis as its first Chief Scientific Officer (CSO).

ArcticZymes Technologies has today appointed Dr. Darren Ellis as its first Chief Scientific Officer. Dr. Ellis brings over 20 years of industrial R&D experience (from Solexa (now Illumina) and ThermoFisher Scientific) in leading and developing molecular research and In Vitro Diagnostic (IVD) applications, technologies and products. Furthermore, he has global expertise in Business-to-Business (B2B) application development, successfully helping commercial partners and customers to bring their technologies and product developments to market.

Dr. Ellis joined the Company in March this year to lead the establishment of the Application Laboratory at Oslo Science Park and to recruit an experienced team of application scientists. The laboratory is operational and currently focussing on the development of workflow applications related to infectious disease testing.

As CSO, Dr. Ellis will support the Company to strategically expand and optimise the Company´s innovation capabilities and efforts in Norway and internationally as the Company grows both organically and inorganically. He will lead an international and experienced scientific team with the ability to bring further cutting edge and high-value innovations to market, hence, elevating the innovation pipeline to the next level.

ArcticZymes Technologies ASA, CEO, Jethro Holter said:

"ArcticZymes is delighted to welcome Dr. Ellis as CSO. I had the pleasure to work directly with Darren earlier in my career in supporting commercial partners to market with world leading technologies."

Dr. Darren Ellis, ArcticZymes Technologies, CSO, said:

"I am pleased to be joining ArcticZymes as CSO at this exciting phase of the Company´s growth journey and to lead future technology development. The Company has a strong product portfolio, an innovative pipeline and a great reputation with our customers. I am looking forward to working with a highly accomplished and international team to achieve our mission to become Europe's leading independent enzyme manufacturer."

For more information, please contact: ArcticZymes Technologies CEO, Jethro Holter CFO, Børge Sørvoll

Tel: +47 46 85 91 46 Tel: +47 95 29 01 87 ir@arcticzymes.com

About ArcticZymes Technologies ASA

ArcticZymes Technologies is a Norwegian life sciences company focused on the development, manufacturing and commercialization of novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing.

Listed on the Oslo Stock Exchange since 2005 originally under the [Biotec] ticker, as Biotec Pharmacon. The company rebranded as ArcticZymes Technologies in 2020 under the [AZT] ticker. Its headquarters are based in Tromsø, Norway, at the SIVA Innovation Centre.

ArcticZymes Technologies' IP and capabilities are protected via a large portfolio of patents.

For more information, please visit the website: www.arcticzymes.com.